Skip to main content
Top
Published in: BMC Medical Research Methodology 1/2019

Open Access 01-12-2019 | Research article

Illustration of different modelling assumptions for estimation of loss in expectation of life due to cancer

Authors: Therese M.-L. Andersson, Mark J. Rutherford, Paul C. Lambert

Published in: BMC Medical Research Methodology | Issue 1/2019

Login to get access

Abstract

Background

The life expectancy of cancer patients, and the loss in expectation of life as compared to the life expectancy without cancer, is a useful measure of cancer patient survival and complement the more commonly reported 5-year survival. The estimation of life expectancy and loss in expectation of life generally requires extrapolation of the survival function, since the follow-up is not long enough for the survival function to reach 0. We have previously shown that the survival of the cancer patients can be extrapolated by breaking down the all-cause survival into two component parts, the expected survival and the relative survival, and make assumptions for extrapolation of these functions independently. When extrapolating survival from a model including covariates such as calendar year, age at diagnosis and deprivation status, care has to be taken regarding the assumptions underlying the extrapolation. There are often different alternative ways for modelling covariate effects or for assumptions regarding the extrapolation.

Methods

In this paper we describe and discuss different alternative approaches for extrapolation of survival when estimating life expectancy and loss in expectation of life for cancer patients. Flexible parametric models within a relative survival setting are used, and examples are presented using data on colon cancer in England.

Results

Generally, the different modelling assumptions and approaches give small differences in the estimates of loss in expectation of life, however, the results can differ for younger ages and for conditional estimates.

Conclusion

Sensitivity analyses should be performed to evaluate the effect of the assumptions made when modelling and extrapolating survival to estimate the loss in expectation of life.
Literature
1.
go back to reference Viscomi S, Pastore G, Dama E, Zuccolo L, Pearce N, Merletti F, Magnani C. Life expectancy as an indicator of outcome in follow-up of population-based cancer registries: the example of childhood leukemia. Ann Oncol. 2006; 17(1):167–71.CrossRef Viscomi S, Pastore G, Dama E, Zuccolo L, Pearce N, Merletti F, Magnani C. Life expectancy as an indicator of outcome in follow-up of population-based cancer registries: the example of childhood leukemia. Ann Oncol. 2006; 17(1):167–71.CrossRef
2.
go back to reference Brown ML, Lipscomb J, Snyder C. The burden of illness of cancer: economic cost and quality of life. Annu Rev Public Health. 2001; 22:91–113.CrossRef Brown ML, Lipscomb J, Snyder C. The burden of illness of cancer: economic cost and quality of life. Annu Rev Public Health. 2001; 22:91–113.CrossRef
3.
go back to reference Hakama M, Hakulinen T. Estimating the expectation of life in cancer survival studies with incomplete follow-up information. J Chronic Dis. 1977; 30:585–97.CrossRef Hakama M, Hakulinen T. Estimating the expectation of life in cancer survival studies with incomplete follow-up information. J Chronic Dis. 1977; 30:585–97.CrossRef
4.
go back to reference Rutherford MJ, Andersson TM, Björkholm M, Lambert PC. Loss in life expectancy and gain in life years as measures of cancer impact. Cancer Epidemiol. 2019; 60:168–73.CrossRef Rutherford MJ, Andersson TM, Björkholm M, Lambert PC. Loss in life expectancy and gain in life years as measures of cancer impact. Cancer Epidemiol. 2019; 60:168–73.CrossRef
5.
go back to reference Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. J Clin Oncol. 2016; 34(24):2851–7.CrossRef Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. J Clin Oncol. 2016; 34(24):2851–7.CrossRef
6.
go back to reference Syriopoulou E, Bower H, Andersson TM, Lambert PC, Rutherford MJ. Estimating the impact of a cancer diagnosis on life expectancy by socio-economic group for a range of cancer types in England. Br J Cancer. 2017; 117(9):1419–26.CrossRef Syriopoulou E, Bower H, Andersson TM, Lambert PC, Rutherford MJ. Estimating the impact of a cancer diagnosis on life expectancy by socio-economic group for a range of cancer types in England. Br J Cancer. 2017; 117(9):1419–26.CrossRef
7.
go back to reference Andersson TML, Dickman PW, Eloranta S, Lambe M, Lambert PC. Estimating the loss in expectation of life due to cancer using flexible parametric survival models. Stat Med. 2013; 32:5286–300.CrossRef Andersson TML, Dickman PW, Eloranta S, Lambe M, Lambert PC. Estimating the loss in expectation of life due to cancer using flexible parametric survival models. Stat Med. 2013; 32:5286–300.CrossRef
8.
go back to reference Messori A, Trippoli S. A new method for expressing survival and life expectancy in lifetime cost-effectiveness studies that evaluate cancer patients (review). Oncol Rep. 1999; 6:1135–41.PubMed Messori A, Trippoli S. A new method for expressing survival and life expectancy in lifetime cost-effectiveness studies that evaluate cancer patients (review). Oncol Rep. 1999; 6:1135–41.PubMed
9.
go back to reference Chu P-C, Wang J-D, Hwang J-S, Chang Y-Y. Estimation of life expextancy and the expected years of life lost in patients with major caners: extrapolation of survival curve under high-censored rates. Value Health. 2008; 11:1102–9.CrossRef Chu P-C, Wang J-D, Hwang J-S, Chang Y-Y. Estimation of life expextancy and the expected years of life lost in patients with major caners: extrapolation of survival curve under high-censored rates. Value Health. 2008; 11:1102–9.CrossRef
10.
go back to reference Dickman PW, Adami HO. Interpreting trends in cancer patient survival. J Intern Med. 2006; 260(2):103–17.CrossRef Dickman PW, Adami HO. Interpreting trends in cancer patient survival. J Intern Med. 2006; 260(2):103–17.CrossRef
11.
go back to reference Rutherford MJ, Dickman PW, Lambert PC. Comparison of methods for calculating relative survival in population-based studies. Cancer Epidemiol. 2012; 36(1):16–21.CrossRef Rutherford MJ, Dickman PW, Lambert PC. Comparison of methods for calculating relative survival in population-based studies. Cancer Epidemiol. 2012; 36(1):16–21.CrossRef
12.
go back to reference Royston P, Parmar MKB. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002; 21(15):2175–97.CrossRef Royston P, Parmar MKB. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002; 21(15):2175–97.CrossRef
13.
go back to reference Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Stata J. 2009; 9(2):265–90.CrossRef Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Stata J. 2009; 9(2):265–90.CrossRef
14.
go back to reference Royston P. Flexible parametric alternatives to the Cox model, and more. Stata J. 2001; 1:1–28.CrossRef Royston P. Flexible parametric alternatives to the Cox model, and more. Stata J. 2001; 1:1–28.CrossRef
15.
go back to reference Nelson CP, Lambert PC, Squire IB, Jones DR. Flexible parametric models for relative survival, with application in coronary heart disease. Stat Med. 2007; 26(30):5486–98.CrossRef Nelson CP, Lambert PC, Squire IB, Jones DR. Flexible parametric models for relative survival, with application in coronary heart disease. Stat Med. 2007; 26(30):5486–98.CrossRef
16.
go back to reference Andersson TML, Dickman PW, Eloranta S, Lambert PC. Estimating and modelling cure in population-based cancer studies within the framework of flexible parametric survival models. BMC Med Res Methodol. 2011; 11(1):96.CrossRef Andersson TML, Dickman PW, Eloranta S, Lambert PC. Estimating and modelling cure in population-based cancer studies within the framework of flexible parametric survival models. BMC Med Res Methodol. 2011; 11(1):96.CrossRef
17.
go back to reference Brenner H, Gefeller O. Deriving more up-to-date estimates of long-term patient survival. J Clin Epidemiol. 1997; 50(2):211–6.CrossRef Brenner H, Gefeller O. Deriving more up-to-date estimates of long-term patient survival. J Clin Epidemiol. 1997; 50(2):211–6.CrossRef
18.
go back to reference Talbäck M, Dickman PW. Predicting the survival of cancer patients recently diagnosed in Sweden and an evaluation of predictions published in 2004. Acta Oncol. 2012; 51(1):17–27.CrossRef Talbäck M, Dickman PW. Predicting the survival of cancer patients recently diagnosed in Sweden and an evaluation of predictions published in 2004. Acta Oncol. 2012; 51(1):17–27.CrossRef
19.
go back to reference Rutherford MJ, Crowther MJ, Lambert PC. The use of restricted cubic splines to approximate complex hazard functions in the analysis of time-to-event data: a simulation study. J Stat Comput Simul. 2015; 85(4):777–93.CrossRef Rutherford MJ, Crowther MJ, Lambert PC. The use of restricted cubic splines to approximate complex hazard functions in the analysis of time-to-event data: a simulation study. J Stat Comput Simul. 2015; 85(4):777–93.CrossRef
20.
go back to reference Royston P, Parmar MKB. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol. 2013; 13:152.CrossRef Royston P, Parmar MKB. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol. 2013; 13:152.CrossRef
21.
go back to reference Dehbi H-M, Royston P, Hackshaw A. Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards. BMJ (Clin Res ed.) 2017; 357:j2250.CrossRef Dehbi H-M, Royston P, Hackshaw A. Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards. BMJ (Clin Res ed.) 2017; 357:j2250.CrossRef
22.
go back to reference Andersen PK. Life years lost among patients with a given disease. Stat Med. 2017; 36:3573–82.CrossRef Andersen PK. Life years lost among patients with a given disease. Stat Med. 2017; 36:3573–82.CrossRef
23.
go back to reference Burnet N, Jefferies S, Benson R, Hunt D, Treasure F. Years of life lost (YLL) from cancer is an important measure of population burden—and should be considered when allocating research funds. Br J Cancer. 2005; 92(2):241–5.CrossRef Burnet N, Jefferies S, Benson R, Hunt D, Treasure F. Years of life lost (YLL) from cancer is an important measure of population burden—and should be considered when allocating research funds. Br J Cancer. 2005; 92(2):241–5.CrossRef
24.
go back to reference Yabroff KR, Bradley CJ, Mariotto AM, Brown ML, Feuer EJ. Estimates and projections of value of life lost from cancer deaths in the United States. J Natl Cancer Inst. 2008; 100:1755–62.CrossRef Yabroff KR, Bradley CJ, Mariotto AM, Brown ML, Feuer EJ. Estimates and projections of value of life lost from cancer deaths in the United States. J Natl Cancer Inst. 2008; 100:1755–62.CrossRef
25.
go back to reference Silversmit G, Vaes E, van Eycken L. Estimation of population-based cancer-specific potential years of life lost in belgium. Eur J Cancer Prev. 2017; 26:S157–63.CrossRef Silversmit G, Vaes E, van Eycken L. Estimation of population-based cancer-specific potential years of life lost in belgium. Eur J Cancer Prev. 2017; 26:S157–63.CrossRef
Metadata
Title
Illustration of different modelling assumptions for estimation of loss in expectation of life due to cancer
Authors
Therese M.-L. Andersson
Mark J. Rutherford
Paul C. Lambert
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Medical Research Methodology / Issue 1/2019
Electronic ISSN: 1471-2288
DOI
https://doi.org/10.1186/s12874-019-0785-x

Other articles of this Issue 1/2019

BMC Medical Research Methodology 1/2019 Go to the issue